Figure 4.

Synergy between A-1210477 and BCL-2 family inhibitors correlates with that observed between flavopiridol and BCL-2 family inhibitors. BCL2^High NHL cell lines were co-treated with navitoclax (0–20 μM), venetoclax (0–20 μM) or A-1155463 (0.20 μM) in combination with flavopiridol (0, 16.67, 50 and 150 nM) for 48 h and the effect on viability determined (a). Synergy was quantified by Bliss analysis (b). Data are presented as the mean±s.e.m. of three independent experiments. Bliss sums obtained in both BCL2^High and BCL2^Low NHL cell lines treated with A-1210477 in combination with navitoclax, venetoclax or A-1155463 were then correlated with those obtained with flavopiridol and navitoclax, venetoclax or A-1155463 (c). Data points represent the mean of three independent experiments. Spearman rank correlation co-efficient and associated statistical significance was determined using GraphPad Prism.